Aptimmune Biologics has completed its Series B funding initiative, raising more than $6 million from several investors. This increases the combined total investment to almost $9 million, generated by the company through three rounds of funding.
“Aptimmune is thrilled to receive strong investor support during this critical time in our development,” said Aaron Gilbertie, Aptimmune CEO. “The Series B funds will provide the required resources to continue commercialization of BarricadeTM, our revolutionary inactivated mucosal vaccine formulation. In addition, the fresh cash infusion will allow us to expand our vaccine platform to other antigens important to veterinarians and swine producers around the globe.”
Participants in the company’s Series B funding include St. Louis Arch Angels, Arsenal Capital Management, Missouri Technology Corporation, Cultivation Capital, The Yield Lab, and various Midwest-based angel investors.
“St. Louis Arch Angels invested in Aptimmune starting in the fall 2016, and since that time we’ve observed the company’s steady progress, technically and commercially,” said Steve Wilhelm with Arch Angels. “We believe in Aptimmune’s mission and team and are pleased to extend our investment in Aptimmune as it changes vaccine paradigms and improves outcomes for customers.”










